---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-001314"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:27:41.084579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma reports favorable Phase 1 safety/tolerability for oral antiviral CDI-988 at 800 mg for 10 days

## Summary
- Phase 1 MAD study shows CDI-988 well-tolerated up to 800 mg/day for 10 days; new cohort at 1,200 mg for 5 days planned.
- Pan-viral inhibitor targets norovirus and coronaviruses; no approved antivirals for norovirus exist.
- Company plans to start human challenge study in norovirus-infected subjects later in 2025.
- Norovirus outbreaks surge in U.S.; CDC estimates 21 million annual U.S. cases and $10.6B economic burden.

## SEC filing metadata
- accession: 0001493152-25-001314
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315225001314/0001493152-25-001314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315225001314/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-001314
- JSON: https://secwatch.observer/filing/0001493152-25-001314.json
- Plain text: https://secwatch.observer/filing/0001493152-25-001314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.